Cadrenal Therapeutics is a biopharmaceutical company developing a late-stage novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation (ESRD + AFib).
Commonly prescribed treatments for patients with ESRD + AFib may cause substantial harm, leading to outcomes such as stroke, systemic embolism, major bleeding, or death. Yet most trials of anticoagulant therapy to reduce the risk of such events have excluded these patients.
We are focused on advancing the development of tecarfarin, a novel Phase 3-ready, oral anticoagulant designed using a retrometabolic drug design process which targets a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. This potentially gives tecarfarin a better safety profile and potentially eliminates specific side effects while maintaining or improving efficacy.
Clinical Trials
Tecarfarin has been evaluated in 11 human clinical trials in over 1,000 individuals.
In Phase 1, Phase 2 and Phase 2/3 clinical trials that have been conducted thus far, tecarfarin has generally been well-tolerated in both healthy adult patients and patients with chronic kidney disease.
We are currently focused on advancing our pivotal Phase 3 trial.
Tecarfarin, a novel therapy designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with End Stage Renal Disease and Atrial Fibrillation, may be a new treatment option for this underserved patient
PONTE VEDRA, Fla., Feb. 8, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and
PONTE VEDRA, Fla., Feb. 6, 2023 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and
Cadrenal Therapeutics, Inc.
822 North A1A
Ponte Vedra, FL 32082
[email protected]
Copyright 2023 Cadrenal Therapeutics. All Rights Reserved.